Published online before print December 9, 2002, doi: 10.1161/01.CIR.0000043245.00859.11
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:81.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
Sustained Hemodynamic Effects of Intravenous Levosimendan
From the Cardiomyopathy Program and Cardiovascular Medicine Section (W.S.C.), Boston University Medical Center, Boston, Mass, and Orion Pharma (M.K., L.L.), Clinical Research, Espoo, Finland.
Correspondence to Wilson S. Colucci, MD, Cardiovascular Section, Boston University Medical Center, 88 E Newton St, Boston, MA 02118. E-mail wilson.colucci{at}bmc.org
Background— The short-term infusion of levosimendan (Levo) improves hemodynamic function in patients with decompensated heart failure. The metabolites of Levo have a prolonged half-life, and one is hemodynamically active. The goal of this study was to determine whether the hemodynamic effects of Levo are sustained during a long-term infusion and beyond the discontinuation of drug infusion.
Methods and Results— Patients with decompensated heart failure received escalating infusion rates of intravenous Levo (n=98) or placebo (n=48) for 6 hours. At the end of 6 hours, 85 of the Levo-treated patients were continued on open-label drug for a total of 24 hours, at which time they were randomized 1:1 to an additional 24 hours of Levo (n=43) or placebo (n=42).The hemodynamic effects observed at 24 hours were maintained at 48 hours in both the continuation and withdrawal groups and did not differ between groups. Although the plasma concentration of Levo decreased rapidly in the withdrawal group, concentrations of the active metabolite OR-1896 were similar in the continuation and withdrawal groups at 24 hours and increased further (3.5-fold to 4-fold) and to a similar extent in both groups at 48 hours.
Conclusions— The hemodynamic effects of Levo were maintained during a 48-hour continuous infusion and for at least 24 hours after discontinuation of a 24-hour infusion. The active metabolite OR-1896 increased for at least 24 hours after cessation of drug infusion and may account for the prolonged hemodynamic effects of Levo.
Key Words: heart failure • inotropic agents • vasodilators
This article has been cited by other articles:
 |
|
 |
|
  D. Cunha-Goncalves, V. Perez-de-Sa, A. Larsson, J. Thorne, and S. Blomquist Inotropic Support During Experimental Endotoxemic Shock: Part II. A Comparison of Levosimendan with Dobutamine Anesth. Analg., November 1, 2009; 109(5): 1576 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Shekerdemian Perioperative manipulation of the circulation in children with congenital heart disease Heart, August 1, 2009; 95(15): 1286 - 1296. [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. H. van Hees, P. N. R. Dekhuijzen, and L. M. A. Heunks Levosimendan Enhances Force Generation of Diaphragm Muscle from Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 1, 2009; 179(1): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. X. Kleber, T. Bollmann, M. M. Borst, A. Costard-Jackle, R. Ewert, M. Kivikko, T. Petterson, P. Pohjanjousi, S. Sonntag, and G. Wikstrom Repetitive Dosing of Intravenous Levosimendan Improves Pulmonary Hemodynamics in Patients With Pulmonary Hypertension: Results of a Pilot Study J. Clin. Pharmacol., January 1, 2009; 49(1): 109 - 115. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Vanek, M. Kolesar, M. Nejedly, and R. Jirmar Rescue peri-operative management of the patient with giant electrical storm and severe left ventricular dysfunction: support by levosimendan and intraaortic balloon counterpulsation Interactive CardioVascular and Thoracic Surgery, August 1, 2008; 7(4): 648 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Puttonen, S. Kantele, A. Ruck, M. Ramela, S. Hakkinen, M. Kivikko, and P. J. Pentikainen Pharmacokinetics of Intravenous Levosimendan and Its Metabolites in Subjects With Hepatic Impairment J. Clin. Pharmacol., April 1, 2008; 48(4): 445 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Lang Management of acute and chronic RV dysfunction Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H61 - H67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tasouli, K. Papadopoulos, T. Antoniou, I. Kriaras, G. Stavridis, D. Degiannis, and S. Geroulanos Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 629 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships Circulation, March 13, 2007; 115(10): 1218 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lilleberg, M. Laine, T. Palkama, M. Kivikko, P. Pohjanjousi, and M. Kupari Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure Eur J Heart Fail, January 1, 2007; 9(1): 75 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-P. Caimmi, E. Grossini, C. Molinari, G. Vacca, and G. Teodori Intracoronary Infusion of Levosimendan to Treat Postpericardiotomy Heart Failure Ann. Thorac. Surg., November 1, 2006; 82(5): e33 - e34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Adamcova, M. Sterba, T. Simunek, A. Potacova, O. Popelova, and V. Gersl Myocardial regulatory proteins and heart failure Eur J Heart Fail, June 1, 2006; 8(4): 333 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Egan, A. J. B. Clarke, S. Williams, A. D. Cole, J. Ayer, S. Jacobe, R. B. Chard, and D. S. Winlaw Levosimendan for Low Cardiac Output: A Pediatric Experience J Intensive Care Med, May 1, 2006; 21(3): 183 - 187. [Abstract] [PDF]
|
|
|
|
|
|
S. G. Raja and B. S. Rayen Levosimendan in Cardiac Surgery: Current Best Available Evidence Ann. Thorac. Surg., April 1, 2006; 81(4): 1536 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Kass and R. J. Solaro Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart Circulation, January 17, 2006; 113(2): 305 - 315. [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Earl and J. T Fitzpatrick Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure Ann. Pharmacother., November 1, 2005; 39(11): 1888 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. R. Dopfmer, J. P. Braun, J. Grosse, and W. Konertz Temporary left ventricular assist and levosimendan for coronary artery spasm Interactive CardioVascular and Thoracic Surgery, August 1, 2005; 4(4): 316 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Avgeropoulou, I. Andreadou, S. Markantonis-Kyroudis, M. Demopoulou, P. Missovoulos, A. Androulakis, and I. Kallikazaros The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine Eur J Heart Fail, August 1, 2005; 7(5): 882 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Endorsed by the European Society of Intensive Care, Authors/Task Force Members, M. S. Nieminen, M. Bohm, M. R. Cowie, H. Drexler, G. S. Filippatos, G. Jondeau, Y. Hasin, J. Lopez-Sendon, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology Eur. Heart J., February 2, 2005; 26(4): 384 - 416. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J.V. McMurray and M. A. Pfeffer The year in heart failure J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2398 - 2405. [Full Text] [PDF]
|
|
|
|
|
|
P. Poder, J. Eha, S. Sundberg, S. Antila, M. Heinpalu, I. Loogna, U. Planken, S. Rantanen, and L. Lehtonen Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval Study J. Clin. Pharmacol., October 1, 2004; 44(10): 1143 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gegenhuber, T. Mueller, F. Firlinger, K. Lenz, W. Poelz, and M. Haltmayer Time Course of B-Type Natriuretic Peptide (BNP) and N-Terminal ProBNP Changes in Patients with Decompensated Heart Failure Clin. Chem., February 1, 2004; 50(2): 454 - 456. [Full Text] [PDF]
|
|